MabCure, Inc. (MBCI)

Market Cap	11.72K -85.0%
Revenue (ttm)	500.00K
Net Income	-12.26M
EPS	-0.19
Shares Out	781.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,408
Open	n/a
Previous Close	0.0005
Day's Range	n/a
52-Week Range	n/a
Beta	-25.17
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About MabCure

MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure, Inc. in January 2008 to reflect its new business plan. MabCure, Inc. was founded in 2006 and is based in White Pla...

• Industry: Solar
• Sector: Technology
• Founded: 2006
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: MBCI

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 2, 2026

Data Sources Report a data error